page 1ENTHEON BIOMEDICAL CORP. all rights reserved©

a new dimension inaddiction treatment

Entheon is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.

DMT and addiction

Addiction treatment success rates are so low that society has been conditioned to accept – and even expect – failure. This manner of thinking is both unacceptable and counterproductive. There is a need for an alternative approach, one that addresses and serves to remedy the human cost of addiction for individuals, families and society at large.

Entheon is developing a DMT-assisted therapeu-tic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeu-tic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives.

Scientific & Regulatory Pathway

Entheon has begun the formal process of beginning clinical trials with DMT with a Contract Research Organization partner; has filed provisional patents in connection with DMT therapy as an addiction treatment; and will be pursuing full FDA, Health Canada, and EMA regulatory approval.

our team

Officer

Timothy KoChief Executive Broad background of leading private ventures in different sectors

Andrew HegleDirector of Operation

Adjunct Professor of Pharmacology at the University of British Columbia

Brandon SchwabeChief Financial OfficerA decade of professional experience in finance and accounting

Yaron EshelProject ManagerLed clinical trials and worked with CRO’s all over the world

Christoper GondiDirectorDepts. of Medicine, Surgery and Pathology at the University of Illinois

scientific advisors

Matthew W. JohnsonPh.D., M.Sc.Professor of Psychiatry and BehavioralSciences, Johns Hopkins

Robin-Carhart HarrisPh.D.

Head, The Psychedelic Research Group, ImperialCollege London

Dennis McKennaPh.D.Ethnopharmacologist, researchpharmacognosist, lecturer and author

Christopher TimmermanPh.D.Lead Researcher, The Psychedelic ResearchGroup, Imperial College London

Malin Vedøy UthaugPh.D.Research Assist., Centre for PsychedelicResearch, Imperial College of London

Kenneth TupperPh.D.

Director, Substance Use Prevention & HarmReduction, BC Ministry of Health

Dr. Michael WalkerProf. Emeritus Anesthesiology, Pharmacologyand Therapeutics, UBC

page 2ENTHEON BIOMEDICAL CORP. all rights reserved©

Ph.D. M.Sc.

CPA CGA

Ph.D.

Ruth ChunBoard MemberHon. BA (Trinity College) and MA from theUniversity of Toronto and Juris Doctor fromQueens University

M.A. J.D.

page 3ENTHEON BIOMEDICAL CORP. all rights reserved©

financials

51,830,618Fully Diluted

11,171,767Warrants

40,388,851Outstanding Shares

Share Structure

Learn more about Entheon

entheonbiomedical.com

@entheonbiomed fb.com/entheonbiomedical linkedin.com/company/entheon

info@entheonbiomedical.com

Visit us on social media

2020Entheon formed and incorporated Formation of management team and scientific advisory board Comprehensive Literature Review 4 provisional patents filed in the US DMT Drug Supply Agreement with Psygen Labs Inc. Signed Contract for clinical program with Centre for Human Drug Research signed Entheon Listed on the CSE Meeting with Dutch Regulators to discuss upcoming CHDR Clinical Trial

2021Health Canada Discussions European Regulatory DiscussionsDMT/Smoking Cessation Clinical Trial at CHDR to begin Health Canada Discussions European Regulatory Discussions Initial Meeting with FDA to outline path for upcoming clinical trials

2022+Formality One Study PK, 1, 2a IV Formality Two Study, PK, 1, 2a IVLicensing of Nicotine-Use Disorder Indication Phase 1/2a Study – Opioid-Use disorder Phase 2b/3 Study – Nicotine-Use Disorder, multicenterPhase 2b Study – Opioid-Use DisorderPhase 2b Study – Alcohol-Use DisorderNDA SubmissionFDA Approval

TIMELINEESTIMATED